Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03351114 · ClinicalTrials.gov registry record · Phase 2
Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
A Phase 2 study of Morphea, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT03351114: Completed Phase 2 study of Morphea, sponsored by Duke University.
NCT03351114 is a Phase 2 study of Morphea that has completed, run by Duke University. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03351114, a Phase 2 study of Morphea, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.
Primary Outcome
Change in dermal thickness on skin biopsy. A sentinel plaque will be selected at baseline. A 4 mm skin punch biopsy will be performed at baseline and at 12 weeks, on the same affected plaque.
Conditions Studied
Interventions
- DRUG Crisaborole
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2020-03-10 |
| Phase | Phase 2 |
What the finished NCT03351114 record still lists
NCT03351114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Morphea appearing as the primary indexed condition, and to 1 intervention - of which Crisaborole is the first listed.
NCT03351114 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03351114 about?
NCT03351114 is a clinical study titled "Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea". This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.
What is the current status of trial NCT03351114?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2018-09-01. Estimated completion is 2020-03-10.
What conditions does trial NCT03351114 study?
This clinical trial studies the following conditions: Morphea.
What interventions are being tested in trial NCT03351114?
The interventions under investigation include: Crisaborole (DRUG).
Who is sponsoring clinical trial NCT03351114?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03351114 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Morphea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03351114's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI